Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl adByBruce GilPublishedFebruary 14, 2025
Ozempic and other weight loss drugs may be linked to conditions that could lead to blindness, study saysByBruce GilPublishedFebruary 11, 2025
Hims & Hers' off-brand weight loss drugs made a Super Bowl splash. Here's what to knowByBruce GilUpdatedMonday 11:03AM
Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundupByBruce GilPublishedFebruary 7, 2025
Big drama around the Hims & Hers Super Bowl ad is making its way to the FDAByBruce GilPublishedFebruary 6, 2025
Pfizer's CEO is 'cautiously optimistic' about RFK Jr. as Trump's health secretaryByBruce GilUpdatedFebruary 4, 2025
Trump's tariffs could exacerbate drug shortages and raise prices, industry warnsByBruce GilPublishedFebruary 3, 2025
The FDA approved a new non-opioid painkiller. Its maker's stock is risingByWilliam GavinUpdatedJanuary 31, 2025
Trump's Medicaid freeze, Ozempic for kidney disease, and 23andMe for sale: Pharma news roundupByBruce GilPublishedJanuary 31, 2025
The Trump administration promises 'greater transparency' in drug price negotiationsByBruce GilPublishedJanuary 29, 2025
RFK Jr. is open to lowering drug prices — using a policy championed by Elizabeth WarrenByBruce GilUpdatedJanuary 28, 2025
